2. Johnson & Johnson - Top 15 R&D Budgets

Who: Johnson & Johnson

Based: United States

2006 Pipeline Budget: $7.9 billion (€5.40B)

2007 Pipeline News: This year, J&J’s pipeline seemed to take a back seat to the controversy surrounding anemia drug safety. But analysts weren’t too busy speculating over the drugmaker’s anemia drug woes to take note of J&J’s anticipated slowdown in growth. J&J has several late-stage drugs that hold the key to the company’s future. These include telaprevir, two HIV drugs, golimumab [1] (which it's developing with Schering-Plough) and rivaroxaban. Company officials anticipate 18 to 21 new drug filings or approvals over the next three years; five of those are expected by the end of 2007.

Pending Approval:

> Concerta - Adult ADHD
> Remicade - Pediatric Ulcerative Colitis, UC colectomy avoidance
> Ceftobiprole - Complicated Skin and Skin Structure Infections
> Doribax - Nosocomial Pneumonia
> TMC125 - NNRTI HIV/AIDS treatment-experienced patients

Phase III:

> Invega (paliperidone ER OROS) - Bipolar mania
> Paliperidone palmitate IM long acting injectable - Schizophrenia
> Risperdal Consta - Bipolar maintenance, Deltoid injection
> Carisbamate - Epilepsy
> Topomax - Pediatric exclusivity
> CNTO 1275 (ustekinumab) - Psoriasis
> CNTO 148 (golimumab) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis Rheumatoid Arthritis
> Procrit - Chronic Renal Function
> Ceftobiprole - Nosocomial Pneumonia, Hospitalized community acquired pneumonia
> Doxil - Breast Cancer
> Velcade - Non-Hodgkin's Lymphoma, Multiple Myeloma 1st line
> Yondelis - Relapsed Ovarian Cancer
> Dacogen - Injection Myelodysplastic Syndromes
> Prezista - Naïve & early experienced patients
> Tapentadol - Moderate to severe acute pain (IR formulation), moderate to severe chronic pain (ER formulation)
> Rivaroxaban VTE Prophylaxis, knee replacement surgery, stroke prevention in atrial fibrillation, VTE treatment

Full Pipeline Site: Link [2]